Lung disease
Drug research and approvals for lung disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 4,454 studies of lung disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 35 drug trials for it since 2013, and FDA has 3 approved and 6 open orphan designations naming it.
- Recruiting worldwide: 4,454
- Trials authorized in Canada: 35
- FDA orphan approvals: 3
- EU medicines: 0
- Pulmonary Near-infrared Spectroscopy to Predict the Need for Surfactant in Very Low Birth Weight InfantsNCT07950774 · Not reported · University of Stellenbosch · starts Dec 1, 2026
- Improving Vaccine Efficacy for People With Helminth Infection: CORBEVAX in EthiopiaNCT07948395 · Phase 2 / Phase 3 · University of Aarhus · starts Oct 10, 2026
- The PRECISION Partners Platform (P3) StudyNCT07944183 · Not reported · Imperial College London · starts Jun 23, 2026
- A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6…NCT07947056 · Phase 3 · Tuberculosis Research Centre, India · starts Jun 6, 2026
- A Superiority Study of Model-Guided Optimized Dosing Versus Empirical Dosing of Piperacillin/Tazobactam in the…NCT07945275 · Phase 2 · Shandong University · starts Jul 17, 2026
- Exploratory Clinical Study of Autologous Tumor-Infiltrating Lymphocytes (TIL) InjectionNCT07947043 · Phase 1 · Tongji Hospital · starts Apr 22, 2025
- Safety and Effectiveness of Different Interface Models for Non-invasive Ventilation Support for Preterm Newborns With a…NCT07944794 · Not applicable · University of Sao Paulo General Hospital · starts Sep 19, 2025
- Pragmatic AI-Assisted Lung Cancer Translational StudyNCT07941128 · Not applicable · Sir Run Run Shaw Hospital · starts Aug 1, 2026
- A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of…NCT07940881 · Phase 1 · SystImmune Inc. · starts Aug 24, 2026
Approved 5
- AmikacinBacterial 70S ribosome inhibitor
- ItraconazoleCytochrome P450 51 inhibitor
- DoxapramPotassium channel subfamily K member 3 blocker
- Pirfenidone
- .alpha.1-proteinase inhibitor humanLeukocyte elastase inhibitor
Phase 3 12 of 21
- MoxifloxacinTopoisomerase IV inhibitor
- Nitric oxideSoluble guanylate cyclase activator
- AzithromycinBacterial 70S ribosome inhibitor
- CyclophosphamideDNA inhibitor
- AlbuterolBeta-2 adrenergic receptor agonist
- FentanylMu opioid receptor agonist
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- Amphotericin bErgosterol sequestering agent
- FurosemideSodium-(potassium)-chloride cotransporter 2 inhibitor
- RituximabB-lymphocyte antigen CD20 binding agent
- SildenafilPhosphodiesterase 5A inhibitor
- TriamcinoloneGlucocorticoid receptor agonist
Phase 2 12 of 24
- PrednisoneGlucocorticoid receptor agonist
- PF-00610355Beta-2 adrenergic receptor agonist
- AzathioprineAmidophosphoribosyltransferase inhibitor
- BedaquilineATP synthase inhibitor
- CefoxitinBacterial penicillin-binding protein inhibitor
- CyclosporineCyclophilin A modulator
- DoxycyclineMatrix metalloproteinase 7 inhibitor
- SalmeterolBeta-2 adrenergic receptor agonist
- TacrolimusFK506-binding protein 1A inhibitor
- TigecyclineBacterial 70S ribosome inhibitor
- TocilizumabInterleukin-6 receptor alpha subunit inhibitor
- EthambutolArabinosyltransferase A inhibitor
Phase 1 or earlier 3
- CiprofloxacinBacterial DNA gyrase inhibitor
- BupivacaineSodium channel protein type IV alpha subunit blocker
- OxygenEssential for cellular homeostasis
How its trials ended
3,504 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 830 whose ending is known, 55% met their primary endpoint, 10% missed it and 35% stopped early.
- Completed, result not reported1,61946%
- Ongoing58017%
- Status unknown47514%
- Met its primary endpoint45813%
- Stopped: other or unclear1665%
- Missed its primary endpoint852%
- Stopped: enrollment or feasibility602%
- Stopped: sponsor or business decision271%
- Stopped: lack of efficacy241%
- Stopped: funding9<1%
- Stopped: safety1<1%
| Aug 31, 2026 | Imaging measures of respiratory health registryHyperpolarized XENON-129 / Perfluoropropane / Oxygen | The Hospital for Sick Children | Pending |
| Jun 17, 2026 | A double-blind, randomized, placebo-controlled trial investigating the efficacy and safety of nerandomilast over at least 52 weeks in patients with fibrosing…Nerandomilast (bi 1015550) | Boehringer Ingelheim (Canada) Ltd Ltee | Ongoing |
| May 7, 2026 | A phase 1/2, open-label, multi-center, dose escalation, dose expansion, and single repeat dose study of TSRA-196 in adults with the pizz genotype who have lung…TSRA-196 | Tessera Therapeutics, Inc. | Pending |
| Apr 8, 2026 | A study to evaluate the dose-exposure, safety, and exploratory efficacy of nerandomilast in children and adolescents from 2 years to less than 18 years of age…Nerandomilast (bi 1015550) | Boehringer Ingelheim (Canada) Ltd Ltee | Pending |
| Jan 20, 2026 | A phase 3, multicenter, randomized, double-blinded, placebo-controlled study to evaluate the safety and efficacy of L606 (treprostinil liposome inhalation…L606 (treprostinil) | Liquidia Technologies | Ongoing |
| Sep 23, 2025 | A phase 2a, open-label, single arm multicenter exploratory study to evaluate the safety, tolerability, and efficacy of oral doses of ROC-101 in patients with…ROC-101 | Allrock Bio, Inc. | Ongoing |
| Aug 20, 2025 | An open-label study to investigate the long-term safety and efficacy of belimumab in adults with interstitial lung disease (ILD) associated with systemic…Benlysta | GSK | Pending |
| Jul 23, 2024 | Conquest platform clinical study for conquering scleroderma: a multicenter, double-blind, randomized, placebo-controlled, phase 2b platform clinical study to…Nerandomilast (bi 1015550)/ Amlitelimab (SAR445229) | Scleroderma Research Foundation, Inc. | Closed |
| Jul 17, 2024 | A phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of belimumab administered subcutaneously in…Belimumab | GSK | Ongoing |
| Jun 26, 2024 | An open-label extension study of inhaled treprostinil in subjects with fibrotic lung diseaseTreprostinil | United Therapeutics | Ongoing |
| Mar 4, 2021 | ActemraSlowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease | Genentech, Inc. | Approved |
| Sep 6, 2019 | OfevOFEV is indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated interstitial lung… | Boehringer Ingelheim Pharmaceuticals, Inc. | Approved |
| Sep 28, 2018 | ArikayceTreatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not… | Insmed Incorporated | Approved |
| Mar 11, 2020 | PirfenidoneTreatment of Unclassifiable-interstitial lung disease | Legacy Pharma Inc. | Designated |
| Jun 5, 2018 | Nitric oxideTreatment of non-tuberculous mycobacterial lung disease | Novoteris, LLC | Designated |
| Nov 19, 2013 | PirfenidoneTreatment of systemic sclerosis (including the associated interstitial lung disease) | Legacy Pharma Inc. | Designated |
| Sep 27, 2004 | Nitric oxideTo reduce the risk of chronic lung disease in premature neonates | Keenova Therapeutics Ireland Limited | Designated |
| Feb 21, 2001 | PyruvateTreatment of interstitial lung disease. | Cellular Sciences, Inc | Designated |
| Jun 4, 1996 | Selective inhibitor of polymorphonuclear leukocyte (PMN)…Therapeutic management of patients with lung disease attributable to cystic fibrosis. | DuPont Pharmaceuticals Company | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA